Management of invasive aspergillosis in patients with COPD: rational use of voriconazole

Florence Ader, Anne-Lise Bienvenu, Blandine Rammaert, Saad Nseir, Florence Ader, Anne-Lise Bienvenu, Blandine Rammaert, Saad Nseir

Abstract

Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in patients with hematologic malignancies. The reported incidence of IPA in the context of chronic obstructive pulmonary disease (COPD) seems to increase. Approximately 1%-2% of overall fatal cases of IPA occur in COPD patients. The combination of factors such as lung immune imbalance, long-term corticosteroid use, increasing rate of bacterial exacerbations over time, and malnutrition are responsible for the emergence of IPA in these patients. The diagnosis of IPA is difficult to establish, which explains the delay in implementing accurate antifungal therapy and the high mortality rate. Persistent pneumonia nonresponsive to appropriate antibiotic treatment raises the concern of an invasive fungal infection. Definite diagnosis is obtained from tissue biopsy evidencing Aspergillus spp. on microscopic examination or in culture. Culture and microscopy of respiratory tract samples have a sensitivity and specificity of around 50%. Other diagnostic tools can be useful in documenting IPA: computed tomography (CT) scan, nonculture-based tests in serum and/or in bronchoalveolar lavage such as antibody/antigen tests for Aspergillus spp. More recent tools such as polymerase chain reaction or [1-->3]-beta-D-glucan have predictive values that need to be further investigated in COPD patients. Antifungal monotherapy using azole voriconazole is recommended as a first-line treatment of IPA. This review assesses the use of voriconazole in COPD patients.

Keywords: Aspergillus; chronic obstructive pulmonary disease; corticosteroid; invasive pulmonary aspergillosis; voriconazole.

References

    1. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33:1824–1833.
    1. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360.
    1. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis. 1998;26:1473–1475.
    1. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect. 2005;11:427–429.
    1. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782–800.
    1. Samarakoon P, Soubani AO. Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature. Chron Respir Dis. 2008;5:19–27.
    1. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205–216.
    1. Bouza E, Guinea J, Peláez T, Pérez-Molina J, Alcalá L, Munoz P. Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol. 2005;43:2075–2079.
    1. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Crit Care Respir Med. 2007;176:532–555.
    1. Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med. 1986;81:249–254.
    1. Steinbach WJ, Stevens DA. Review of newer antifungal and immuno-modulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37(Suppl 3):S157–187.
    1. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250–260.
    1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366.
    1. Roosen J, Frans E, Wilmer A, Knockaert DC, Bobbaers H. Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings. Mayo Clin Proc. 2000;75:562–567.
    1. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003;15:71–75.
    1. Guinea M, Torres-Narbona P, Gijon T, Pelaez P, Munoz J, De Miguel E, Bouza E. Invasive pulmonary aspergillosis in patients with COPD: A description of 57 cases collected in a single tertiary hospital (1999–2008). Abstract M-2161. Washington, D.C. 48th ICAAC/IDSA 46th Annual Meeting; October 25–28, 2008.
    1. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–540.
    1. Romani L. Immunity to fungal infections. Nat Immunol. 2004;4:1–13.
    1. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–1861.
    1. Seidler MJ, Salvenmoser S, Müller FMC. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Ag Chemoter. 2008;52:4130–4136.
    1. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest. 1985;76:1755–1764.
    1. Diamond RD. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J Infect Dis. 1983;147:160.
    1. Ng TTC, Robson GD, Denning DW. Hydrocortisone enhanced growth of Aspergillus spp: implications for pathogenesis. Microbiology. 1994;140:2475–2479.
    1. Peter E, Bakri F, Ball DM, Cheney RT, Segal BH. Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis. 2002;36:54–56.
    1. Barouky R, Badet M, Saint Denis M, Soubirou JL, Philit F, Guerin C. Inhaled corticosteroids in COPD and disseminated aspergillosis. Eur J Int Med. 2003;14:380–382.
    1. Cornet M, Hallat H, Somme D, et al. Fulminant invasive pulmonary aspergillosis in immunocompetent patients. A two-case report. Clin Microbiol Infect. 2003;9:1224–1227.
    1. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes ARJ, Polderman KH. Immunoparalysis as a cause of invasive aspergillosis. Int Care Med. 2003;29:2068–2071.
    1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
    1. Jantunen E, Piilonen A, Volin L, et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant. 2000;25:867–871.
    1. Kahn FW, Jones JM, England DM. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol. 1986;86:518–523.
    1. Andreas S, Heindl S, Wattky C, Möller K, Rüchel R. Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J. 2000;15:407–411.
    1. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary asper-gillosis in neutropenic patients. Clin Microbiol Infect. 2001;7:54–61.
    1. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171–178.
    1. Kaiser L, Huguenin T, Lew PD, Chapuis B, Pittet D. Invasive aspergillosis Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998;77:188–194.
    1. Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ. The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis. Respir Med. 1992;86:243–248.
    1. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and revew. Clin Infect Dis. 2003;37(S3):S265–280.
    1. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–1610.
    1. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–1427.
    1. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625.
    1. Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2003;41:3922–3925.
    1. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzymenimmunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004;42:5517–5522.
    1. Seyfarth HJ, Nenoff P, Winkler J, Krahl R, Haustein UF, Schauer J. Aspergillus detection in bronchoscopically acquired material. Significance and interpretation. Mycoses. 2001;44:356–360.
    1. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45:1759–1765.
    1. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177:27–34.
    1. Ansorg R, Van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses. 1997;40:353–357.
    1. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003;349:2366–2367.
    1. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin–tazobactam. Clin Infect Dis. 2004;38:913–916.
    1. Becker MJ, De MS, Fens MH, Verbrugh HA, Bakker-Woudenberg IA. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother. 2003;52:428–434.
    1. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–1769.
    1. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the [1–> 3]-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–659.
    1. Okada S, Teramoto S, Takizawa H, Ouchi Y, Matsuoka R. Clinical insignificance of 1–> 3]-β-D-glucan in early diagnosis of invasive pulmonary aspergillosis in a patient with chronic obstructive pulmonary disease. J Med Microb. 2003;52:1031–1032.
    1. Vandewoude KH, Vogelaers D, Blot SI. Aspergillosis in the ICU-the new 21st century problem. Med Mycol. 2006;44:S71–76.
    1. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10:882–885.
    1. Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol. 1999;37:3865–3871.
    1. Bretagne S, Costa JM, Marmorat-Khuong A, et al. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol. 1995;33:1164–1168.
    1. Raad I, Hanna H, Sumoza D, Albitar M. Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients. Cancer. 2002;94:1032–1036.
    1. Raad I, Hanna H, Huaringa A, Sumoza D, Hachem R, Albitar M. Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL. Chest. 2002;121:1171–1176.
    1. Buchheidt D, Baust C, Skladny H, Baldus M, Brauninger S, Hehlmann R. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol. 2002;116:803–811.
    1. White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006;42:479–486.
    1. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly P. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:89–96.
    1. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5:609–622.
    1. Garcia ME, Blanco JL, Caballero J, Gargallo-Viola D. Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol. 2002;40:1567–1568.
    1. Collins J. CT signs and patterns of lung disease. Radiol Clin North Am. 2001;39:1115–1135.
    1. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253–259.
    1. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol. 2005;43:S147–154.
    1. Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis: frequency and meaning of the “hypodense sign” on unenhanced CT. Br J Radiol. 2005;78:697–703.
    1. Kami M, Kishi Y, Hamaki T, et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses. 2002;45:287–294.
    1. Lee YR, Choi YW, Lee KJ, Jeon SC, Park CK, Heo JN. CT halo sign: the spectrum of pulmonary diseases. Br J Radiol. 2005;78:862–865.
    1. Pasmans HL, Loosveld OJ, Schouten HC, Thunnissen F, van Engelshoven JM. Invasive aspergillosis in immunocompromised patients: findings on plain film and (HR) CT. Eur J Radiol. 1992;14:37–40.
    1. Won HJ, Lee KS, Cheon JE, et al. Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia – a prospective study. Radiology. 1998;208:777–782.
    1. Pinto PS. The CT halo sign. Radiology. 2004;230:37–40.
    1. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56:269–276.
    1. Greene RE, Schlamm HT, Stark P, et al. Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air crescent sign for diagnosis and treatment of invasive pulmonary aspergillosis in high-risk patients [abstract]. European Congress of Microbiology and Infectious Diseases, 13th annual meeting; 2003.
    1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415.
    1. Chandrasekar PH, Curtright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother. 2000;45:673–676.
    1. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother. 2000;50:2865–2868.
    1. Takemoto K, Yamamoto Y, Ueda Y, Kanazawa K, Yoshida K, Niki Y. Comparative study on the sfficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy. 2009;55:105–113.
    1. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29:198–210.
    1. Drusano GL. How does a patient maximally benefit from anti-infective chemotherapy. Clin Infect Dis. 2004;39:1245–1246.
    1. Lewis RE. What is the “therapeutic range” for voriconazole. Clin Infect Dis. 2008;46:212–214.
    1. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39:1241–1244.
    1. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995;57:662–669.
    1. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087–1088.
    1. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–211.
    1. Levêque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27:274–284.
    1. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47:e7–e10.
    1. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997–2020.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir